Videos

Bradley J. Stish, MD, emphasized the role of decision-making processes between physicians and patients when deciding between 2.5 and 5 mg of oxybutynin.

Ryan H. Moy, MD, PhD, is the principal investigator of a phase 2 trial evaluating defactinib plus avutometinib in patients with diffuse gastric/GEJ carcinoma.

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss how the clinical development of osimertinib across multiple disease stages has influenced treatment expectations in early-stage EGFR-mutated non–small cell lung cancer (NSCLC).

Panelists engage in a structured debate on whether CAR T-cell therapy for aggressive large B-cell lymphoma should be administered in the inpatient or outpatient setting. Team NYC argues for inpatient treatment in higher-risk or socially complex cases, citing logistical barriers, caregiver limitations, and the need to manage serious toxicities such as CRS and ICANS. Team Roswell counters that outpatient programs can safely expand access, reduce hospital-related complications, and improve patient acceptance of CAR T, prompting a broader discussion on evolving safety data, real-world logistics, and changing regulatory requirements.

In this segment, Dr. Alexander Spira engages Dr. Natalie Vokes in a discussion on the distinct biology of EGFR-mutated non–small cell lung cancer (NSCLC) and how it informs treatment decisions in the early-stage setting.

In this segment on advanced renal cell carcinoma, Dr. Ornstein guides the discussion toward differentiating available frontline treatment options, focusing on the choice between dual immune checkpoint inhibitor therapy and combinations of immunotherapy with VEGF receptor targeted therapies.

In this opening segment on advanced renal cell carcinoma, Dr. Ornstein introduces the evolving frontline treatment landscape, highlighting the expanded role of immune checkpoint inhibitor–based combinations and VEGF receptor targeted therapies.

Jesse Fann, MD, MPH, spoke about what he hopes to accomplish during the 2-year term of his APOS presidency.

Linda E. Carlson, PhD, RPsych, asserted mindfulness programs have strong evidence in managing psychosocial symptoms, but require increasing access for use.

In this segment, the discussion centers on proactive toxicity management strategies in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rous to interpret the clinical implications of the FDA approval of subcutaneous amivantamab in combination with lazertinib, including the availability of once monthly dosing.

Yesne Alici, MD, discussed cancer-related fatigue and cognitive impairment and addressed sleep disturbances and AEs such as anemia to improve outcomes.

It is a good option to move to BCMA-directed therapy for patients with multiple myeloma after an initial relapse, said María-Victoria Mateos, MD, PhD.

PET-negative soft tissue disease may prompt a rebiopsy, particularly in enriching for treatment-emergent neuroendocrine prostate cancers.

NEADORA data highlights why early NGS guides resectable EGFR lung cancer care, favoring perioperative osimertinib and avoiding checkpoint inhibitors.

Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.

Experts explain how adjuvant osimertinib changes post-surgery EGFR lung cancer care, from rapid testing to real-world adherence.

Ryan H. Moy, MD, PhD, noted that patients with early-onset esophagogastric cancer tend to have more advanced disease.

According to Yoanna S. Pumpalova, MD, both early-onset and later-onset colorectal cancers are genetically similar in terms of somatic mutations.

Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.

Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.

It is unlikely that guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”

In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rotow to move beyond clinical trial data and discuss the real world factors that influence first line treatment selection in EGFR mutated metastatic non-small cell lung cancer.

The NHS-Galleri study findings showed that multicancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.